Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Sanofi to Sell Pozen Cardiovascular Drugs in US

By Pharmaceutical Processing | September 4, 2013

Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540.

The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies said Pozen could get additional payments if the drugs are approved, and it will get royalties on any sales.

Pozen will be responsible for handling the rest of the regulatory process and Sanofi will be responsible for sales and manufacturing.

The two drugs combine aspirin with omeprazole, the active ingredient in heartburn drugs like Prilosec. They are intended as an alternative to aspirin as a secondary treatment for the prevention of cardiovascular disease. Many people take aspirin to prevent heart problems, but long-term use can cause ulcers. In Pozen’s drugs, the omeprazole is released as soon as the tablet is taken and the aspirin is released over time.

PA8140 contains 81 milligrams and aspirin and 40 milligrams of omeprazole, and PA32540 contains 325 milligrams of aspirin and 40 grams of omeprazole. The Food and Drug Administration encouraged Pozen to study the lower-dose version, and it is currently reviewing both products.

Shares of Pozen Inc. rose 7 cents to $5.29 on Wednesday. Sanofi shares gained 30 cents to $47.94.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE